Humans ; Thyroid Neoplasms ; pathology ; therapy

Cardiovascular Diseases ; epidemiology ; prevention & control ; China ; epidemiology ; Female ; Humans ; Hypercholesterolemia ; prevention & control ; Hypertension ; prevention & control ; Life Style ; Male ; Risk Factors

Rapid prototyping technology, a kind of novel digital prototyping technology developed in mid-1980s based on a principle of discrete and accumulation, which fabricates a prototype by accurate accumulation of material according to the CAD models or CT data under the control of the computer without any other device. In recent years, it has shown a great application prospect in the field of orthopedics combined with three-dimensional image reconstruction of spiral CT and MRL In this article, review is given on the application development of rapid prototyping technology in orthopedics, such as organ model preparation and surgical planning, customized implant and bone tissue engineering porosity scaffold fabrication.

Objective To investigate the risk factors in the outcome of neonatal pulmonary hemorrhage. Methods A total of 69 cases of neonatal pulmonary hemorrhage from January 2005 to December 2011 were studied. They were divided into 2 groups according to clinical outcome (death or alive). The data of the two groups were compared using single factor analysis. The risk factors were analyzed using multi-factor analysis. Results The death of neonates with pulmonary hemorrhage was correlated with aspiration pneumonia, coagulation abnormalities, DIC, heart failure and MPV. Multi-factor analysis showed that DIC (OR=6.90, 95%CI:1.514-31.419), heart failure (OR=9.62, 95%CI:1.710-54.150) and MPV<11 prior to pulmonary hemorrhage (OR=7.01, 95%CI:1.475-33.312) were the independent risk factors of neonatal pulmonary hemorrhage. Conclusions For the neonatal pulmonary hemorrhage with DIC, heart failure and low MPV, active intervention should be implemented.

Liver transplantation is a valid treatment option for select patients with Hepatocellular Carcinoma HCC and end-stage liver disease. However, in approximately 20% of patients, recurrent HCC is the rate-limiting factor for longterm survival. Despite identification of clinical parameters that may stratify patients at high risk and exhaustive preoperative staging, cancer recurrence is likely the result of microscopic extrahepatic disease. With a desperate donor organ shortage, locoregional ablation techniques and resection are being employed in patients on the waiting list to serve as a bridge to OLT. Further more, some have advocated aggressive surgical resection of isolated metastasis in both the liver and extrahepatic viscera. Whether these creative strategies confer a survival advantage is unknown, requiring longterm follow-up to determine their efficacy.

Leber congenital amaurosis (LCA) is extremely severe hereditary retinal dystrophy,because it leads to congenital bilateral blindness in early childhood.With the development of molecular genetics and the therapeutic gene replacement technology,gene therapy clinical trials have obtained exciting results on the basis of relatively satisfied with preliminary clinical experimental results by adeno-associated virus (AAV) vector-mediated gene therapy in the past decade.These researching methods include intravitreal injection and subretinal space injection of gene vector,and the investigating indexes include evaluations of visual function and safety,such as immune reaction of the animals,ocular histopathological change,complications and bio-distribution of gene sequence.The preliminary success of the LCAⅡ Ⅱ gene therapy will give some clues to the other inherited retinal diseases.This review focuses on the present status of pre-clinical animal experiments of its gene therapy.

The therapeutic management of hepatic portal hypertension in patients with cirrhosis is still a challenge. At present surgical devascularization and shunting play the important roles in treatment of portal hypertension. While some cirrhotic patients can not bear the stress of operation and anesthesia because of inadequat potential hepatic function. So the mortality of operation is very high. With the development of endoscopy,radiological techniques and new materials and equipments, the mini invasive treatments become more important. This review summarizes the current advances of mini invasive treatments of portal hypertension in cirrhosis.

Objective To evaluate the anticancer effect of arsenic trioxide (As 2O 3) on rabbits with hepatic Vx 2 carcinoma by transcatheter arterial infusion (TAI). Methods Rabbits with hepatic Vx 2 carcinoma were treated with As 2O 3 by TAI for 7 d consecutively. The tumor inhibitory rate and the average tumor weight were determined. The morphological changes of the tumor were observed with a transmission electron microscope. bax/bcl 2 and VEGF expressions were examined by immunohistochemistry. Results The average weight of the tumor was 7.99, 6.50, and 4.87 g, and the tumor growth inhibitory rates in the experimental groups were 50.31%, 59 58%, and 69 71%, respectively. Tumor growth was significantly inhibited as compared with that in the NS group ( P

Objective To establish a liquid chromatographic-mass spectrometric method ( LC-MS/MS method ) for determination of dextrorphan in human liver microsome. Methods LC-MS/MS was adopted with carbamazepine serving as an internal standard.The separation was performed on Agilent ZORBAX XDB-C18 column (2.1 mm×50 mm, 3.5μm), with mobile phase consisting of 0. 05% formic acid methanol-0. 05% formic acid in gradient elution. Dextrorphan and carbamazepine were detected on multiple reaction monitoring(MRM)mode by transitions from precursor to production(m/z 258.1→199.1, 237.1→194.1). Results The linear range of dextrorphan concentration was 19.22-768 960 ng.L-1(r=0.999 8), and the lowest quantification limit was 19.22 ng.L-1.The relative recoveries were 94.02%-98.74%, and the RSDs of intra-day and inter-day were within 10%.IC50 of psoralen on CYP2D6 was 0.6μmol.L-1. Conclusion The LC-MS/MS method is proved to be rapid, sensitive and reproducible, psoralen is a strong inhibitor of CYP2D6.